Vaccination with autologous tumor-derived heat-shock protein Gp96 after liver resection for metastatic colorectal cancer

Clinical Cancer Research

Volumn 9, Issue 9, 2003, Pages 3235-3245

  Mazzaferro, Vincenzo ^a   Coppa, Jorgelina ^a   Carrabba, Matteo G ^a   Rivoltini, Licia ^a   Schiavo, Marcello ^a   Regalia, Enrico ^a   Mariani, Luigi ^a   Camerini, Tiziana ^a   Marchianò, Alfonso ^a   Andreola, Salvatore ^a   Camerini, Roberto ^b   Corsi, Marco ^b   Lewis, Jonathan J ^c   Srivastava, Pramod K ^d   Parmiani, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Sigma Tau SpA   (Italy)

^c Antigenics Inc   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GLYCOPROTEIN GP 96; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN PEPTIDE COMPLEX GLYCOPROTEIN GP 96; ONCOPHAGE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; CELLULAR IMMUNITY; CLINICAL ARTICLE; COLORECTAL CANCER; CONFERENCE PAPER; DIARRHEA; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERTENSION; IMMUNE RESPONSE; LIVER METASTASIS; LIVER RESECTION; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; TUMOR IMMUNOLOGY; VACCINATION;

ADULT; AGED; ANTIGENS, CD3; ANTIGENS, CD45; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PEPTIDES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, CHEMOKINE; REGRESSION ANALYSIS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 10744233222     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Kemeny, N., Huang, Y., Cohen, A. M., Shi, W., Conti, J. A., Brennan, M. F., Bertino, J. R., Turnbull, A-D., Sullivan, D., Stockman, J., and Blumgart, L. H. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N. Engl. J. Med., 341: 2039-2048, 1999.
2. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1, 1999.
3. Weiss, L., Grundmann, E., Torhorst, J., Hartveit, F., Moberg, I., Eder, M., Fenoglio-Preiser, C. M., Napier, J., Horne, C. H., Lopez, M. J., Shaw-Dunn, R. I., Sugart, J., Davies, J. D., Day, D. W., and Harlus, J. P. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J. Pathol., 150: 195-203, 1986.
4. Lorenz, M., Staib-Sebler, E., Hochmuth, K., Heinrich, S., Gog, C., Vetter, G., Encke, A., and Muller, H. H. Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin. Oncol., 27: 112-119, 2000.
5. Nordlinger, B., and Rougier, P. Liver metastases from colorectal cancer: the turning point. J. Clin. Oncol., 20: 1442-1445, 2002.
6. Figueras, J., Valls, C., Rafecas, A., Fabregat, J., Ramos, E., and Jaurrieta, E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br. J. Surg., 88: 980-985, 2001.
7. Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., and Blumgart, L. H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg., 230: 309-318, 1999.
8. Kemeny, M. M., Adak, S., Gray, B., Macdonald, J. S., Smith, T., Lipsitz, S., Sigurdson, E. R., O'Dwyer, P. J., and Benson, A. B., III. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J. Clin. Oncol., 20: 1499-1505, 2002.
9. Wolmark, N., Fisher, B., Rockette, H., Redmond, C., Wickerham, D. L., Fisher, E. R., Jones, J., Glass, A., Lerner, H., Lawrence, W., Prager, D., Wexler, M., Evans, J., Cruz, A., Dimitrov, N., Jochimsen, P., et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J. Natl. Cancer Inst. (Bethesda), 80: 30-36, 1988.
10. Vermoken, J., Claessen, A., van Titeren, H., Gall, H. E., Ezinga, R., Meijer, S., Scheper, R. J., Maijer, C. J. L-M., Bloemena, E., Ranson, J. H., Hanna, M. G., Jr., and Pinedo, H. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet, 353: 345-350, 1999.
11. Harris, J., Ryan, L., Hoover, H., Stuart, R. K., Oken, M. M., Benson, A. B., III, Mansour, E., Haller, D. G., Manola, J., and Hanna, M. G. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol., 18: 148-157, 2000.
12. Nagorsen, D., Keilholz, U., Rivoltini, L., Schmittel, A., Letsch, A., Asemissen, A. M., Berger, G., Buhr, H-J., Thiel, E., and Scheibenbogen, C. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res., 60: 4850-4854, 2000.
13. Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M. M., and Enfleman, E. G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA, 98: 8809-8814, 2001.
14. Ishii, T., Udono, H., Yamano, T., Ohta, H., Uenaka, A., Ono, T., Hjizuta, A., Tanaka, N., Srivastava, P. K., and Nakayama, E. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J. Immunol., 162: 1303-1309, 1999.
15. Basu, S., Binder, R. J., Ramalingam, T., and Srivastava, P. K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity, 14: 303-313, 2001.
16. Castelli, C., Ciupitu, A. M., Rini, F., Rivoltini, L., Mazzocchi, A., Kiessling, R., and Parmiani, G. Human heat shock protein 70 peptide complexes specifically activate anti-melanoma T cells. Cancer Res., 61: 222-227, 2001.
17. Ullrich, S. J., Robinson, E. A., Law, L. W., Willingham, and Appella, E. A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc. Natl. Acad. Sci. USA, 83: 3121-3125, 1986.
18. Udono, H., and Srivastava, P. K. Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med., 178: 1391-1396, 1993.
19. Tamura, Y., Peng, P., Liu, K., Daou, M., and Srivastava, P. K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (Wash. DC), 278: 315-318, 1997.
20. Srivastava, P. K., Menoret, A., Basu, S., Binder, R. J., and McQuade, K. L. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity, 8: 657-665, 1998.
21. Janetzki, S., Palla, D., Rosenhauer, V., Lochs, H., Lewis, J. J., and Srivastava, P. K. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int. J. Cancer, 88: 232-238, 2000.
22. Belli, F., Testori, A., Rivoltini, L., Maio, M., Andreola, G., Sertoli, R., Gallino, G., Piris, A., Cattelan, A., Lazzari, I., Carrabba, M., Scita, G., Santantonio, C., Pilla, L., Tragni. G., Lombardo, C., Arienti, F., Marchianò, A., Queirolo, P., Bertolini, F., Cova, A., Lamaj, E., Ascani, L., Camerini, R., Corsi, M., Cascinelli, N., Lewis, J. J., Srivastava. P., and Parmiani, G. Vaccination of metastatic melanoma patients with autologous tumor-derived Heat Shock Protein Peptide-Complex-96: clinical and immunological findings. J. Clin. Oncol., 20: 4169-4180, 2002.
23. Srivastava, P. K., and Jaikaria, N. S. Methods of purification of heat shock protein-peptide complexes for use as vaccines against cancers and infectious diseases. Methods Mol. Biol., 156: 175-186, 2001.
24. Green, S., and Weiss, G. R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Investig. New Drugs. 10: 239-253, 1992.
25. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1994.
26. Lewis, J. J., Janetzki, S., Schaed, S., Panageas, K. S., Wang, S., Williams, L., Meyers, M., Butterworth, L., Livingston, P. O., Chapman, P. B., and Houghton, A. N. Evaluation of CD8(+) T-cell frequencies by the ELISPOT assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int. J. Cancer, 87: 391-398, 2000.
27. Scheibenbogen, C., Romero, P., Rivoltini, L., Herr, W., Schmittel, A., Cerottini, J-C., Woelfel, T., Eggermont, A. M. M., and Keilholz, U. Quantitation of antigen-reactive T cells in peripheral blood by IFN-γ-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J. Immunol. Methods, 244: 81-89, 2000.
28. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.
29. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Sta. Assoc., 53: 457-481, 1958.
30. Chandawarkar, R. Y., Wagh, M. S., and Srivastava, P. K. The dual nature of specific immunological activity of tumor-derived gp 96 preparations. J. Exp. Med., 189: 1437-1442, 1999.
31. Wells, A., and Malkovsky, M. Heat Shock proteins, tumor immunogenicity and antigen presentation: an integrated view. Immunol. Today, 21: 129-132, 2000.
32. Sallusto, F., Lenig, D., Forster, R., Lipp, M., and Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (Lond.), 40: 659-660, 1999.
33. Valmori, D., Scheibenbogen, C., Dutoit, V., Nagorsen, D., Asemissen, A. M., Rubio-Godoy, V., Rimoldi, D., Guillaume, P., Romero, P., Schadendorf, D., Lipp, M., Dietrich, P-Y., Thiel, E., Cerottini, J-C., Liénard, D., and Keilholz, U. Circulating tumor-reactive CD8+ T cells in melanoma patients contain a CD45RA+CCR7- effector subset exerting ax vivo tumor-specific cytolytic activity. Cancer Res., 62: 1743-1750, 2002.
34. Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., and Anichini, A. Cancer immunotherapy with peptide-based vaccines: what have we achieved, where are we going? J. Natl. Cancer Inst. (Bethesda), 94: 805-818, 2002.
35. Multhoff, G., Botzler, C., Jennen, L., Schmidt, J., Ellwart, J., and Issels, R. Heat shock protein 72 on tumor cells. A recognition structure for natural killer cells. J. Immunol., 158: 4341-4350, 1997.
36. Nordlinger, B., Guiguet, M., Vaillant, J. C., Balladur, P., Boudjema, K., Bachellier, P., and Jaeck, D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer (Phila.), 77: 1254-1262, 1996.
37. Minagawa, M., Makuuchi, M., Torzilli, G., Takayama, T., Kawasaki, S., Kosuge, T., Yamamoto, J., and Imamura, H. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann. Surg., 231: 487-499, 2000.
38. Dizon, D. S., and Kemeny, N. Locoregional chemotherapy for metastatic colorectal cancer to the liver. In: H. Bleiberg, N. Kemeny, P. Rougier and Hansjochen, W. (eds), Colorectal Cancer: A Clinical Guide to Therapy, pp. 367-374. London: Martin Dunitz, 2002.